Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2014 Nov 6;19(1):58.
doi: 10.1186/s40001-014-0058-4.

Clinical efficacy of radical nephrectomy versus nephron-sparing surgery on localized renal cell carcinoma

Wentao Li  1 , Yanlei Cheng  2 , Yi Cheng  3 , Hui Ren  4 , Na Han  5
Affiliations
Meta-Analysis

Clinical efficacy of radical nephrectomy versus nephron-sparing surgery on localized renal cell carcinoma

Wentao Li et al. Eur J Med Res. .

Abstract

Background: The aim of the present study was to compare the clinical efficacy of radical nephrectomy (RN) with nephron-sparing surgery (NSS) in treating patients with localized renal cell carcinoma (RCC).

Methods: The literature search was performed in PubMed, MEDLINE Springer, Elsevier Science Direct, Cochrane Library, and Google Scholar up to December 2012. The software Review Manager 5.1 and the STATA software package v.11.0 were used for analyses. The odds ratios (ORs) and its 95% confidence interval (95% CI) were calculated for comparison. Subgroup analyses were performed based on the tumor size of RCC.

Results: In total, 10 studies with 10,174 RCC patients (7,050 treated with RN and 3,124 treated with NSS) were selected. The pooled estimate (OR = 1.58, 95% CI = 1.15-2.15, P = 0.004) showed a significantly lower rate of cancer-specific deaths in the patients treated with NSS compared to RN. However, no statistically significant differences were found in the rate of tumor recurrence (OR = 0.84, 95% CI = 0.67-1.06, P = 0.14) and complications (OR = 0.91, 95% CI = 0.51-1.63, P = 0.74) between the patients treated with NSS and RN. In addition, all the subgroup analyses presented consistent results with the overall analyses.

Conclusions: NSS had no significantly different from RN in tumor recurrence and complications for localized RCC. However, the significantly lower rate of cancer-specific deaths supported the use of NSS not only for RCC with tumor size >4.0 cm but also for tumor sizes ≤4.0 cm compared with RN.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram of screening studies.
Figure 2
Figure 2
Forest plots of cancer-specific death (A), tumor recurrence (B), and complications (C).
Figure 3
Figure 3
Funnel plot of complications.
See this image and copyright information in PMC

References

    1. Motzer RJ, Nanus DM, Russo P, Berg WJ. Renal cell carcinoma. Curr Probl Cancer. 1997;21:185–232. doi: 10.1016/S0147-0272(97)80007-4. - DOI - PubMed
    1. Curti BD. Renal cell carcinoma. JAMA. 2004;292:97–100. doi: 10.1001/jama.292.1.97. - DOI - PubMed
    1. Godley P, Kim SW. Renal cell carcinoma. Curr Opin Oncol. 2002;14:280–285. doi: 10.1097/00001622-200205000-00005. - DOI - PubMed
    1. Wood C, Srivastava P, Bukowski R, Lacombe L, Gorelov AI, Gorelov S, Mulders P, Zielinski H, Hoos A, Teofilovici F. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet. 2008;372:145–154. doi: 10.1016/S0140-6736(08)60697-2. - DOI - PubMed
    1. Robson CJ, Churchill B, Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol. 1969;101:297. - PubMed

Publication types

MeSH terms